Clinical Trial: Physician and Patient Preferences for Cell Therapies in Advanced Solid Tumors

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07813000) titled 'Physician and Patient Preferences for Cell Therapies in Advanced Solid Tumors' on Aug. 19.

Brief Summary: Cell therapies - including chimeric antigen receptor T-cell (CAR-T) therapy, tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor-engineered T-cell (TCR-T) therapy, and natural killer (NK) cell therapy - are emerging treatments for advanced solid tumors. However, their benefit-risk profiles remain uncertain: objective response rates in solid tumors are generally low, treatment-related toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can be severe, and ...